1. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952
- Author
-
José Thomas, Marna G. Bouwhuis, Ghanem Elias Ghanem, Wim H. J. Kruit, Konstantin Stoitchkov, Poulam M. Patel, Veronique Cocquyt, A.M.M. Eggermont, Danielle Lienard, Stefan Suciu, François Sales, Surgery, and Medical Oncology
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Skin Neoplasms ,medicine.medical_treatment ,Antineoplastic Agents ,Kaplan-Meier Estimate ,Interferon alpha-2 ,law.invention ,Young Adult ,Corollary ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Adjuvant therapy ,Biomarkers, Tumor ,Stage iib ,Humans ,Stage (cooking) ,Neoplasm Metastasis ,Melanoma ,Aged ,business.industry ,S100 Proteins ,Interferon-alpha ,Middle Aged ,medicine.disease ,Prognosis ,Recombinant Proteins ,Female ,Lymph ,business ,Adjuvant - Abstract
S100B is a prognostic factor for melanoma as elevated levels correlate with disease progression and poor outcome. We determined its prognostic value based on updated information using serial determinations in stage IIb/III melanoma patients. 211 Patients who participated in the EORTC 18952 trial, evaluating efficacy of adjuvant intermediate doses of interferon alpha 2b (IFN) versus observation, entered a corollary study. Over a period of 36 months, 918 serum samples were collected. The Cox time-dependent model was used to assess prognostic value of the latest (most recent) S100B determination. At first measurement, 178 patients had S100B values = 0.2 mu g/l. Within the first group, 61 patients had, later on, an increased value of S100B (>= 0.2 mu g/l). An initial increased value of S100B, or during follow-up, was associated with worse distant metastasis-free survival (DMFS); hazard ratio (HR) of S100B >= 0.2 versus S100B < 0.2 was 5.57 (95% confidence interval (CI) 3.81-8.16), P < 0.0001, after adjustment for stage, number of lymph nodes and sex. In stage lib patients, the HR adjusted for sex was 2.14 (95% CI 0.71, 6.42), whereas in stage III, the HR adjusted for stage, number of lymph nodes and sex was 6.76 (95% CI 4.50-10.16). Similar results were observed regarding overall survival (OS). Serial determination of S100B in stage IIb-III melanoma is a strong independent prognostic marker, even stronger compared to stage and number of positive lymph nodes. The prognostic impact of S100B >= 0.2 mu g/l more pronounced in stage III disease compared with stage IIb. (C) 2010 Elsevier Ltd. All rights reserved.
- Published
- 2011